By using this site, you agree to the Privacy Policy and Terms of Use.
Accept
Concealed RepublicanConcealed Republican
  • Home
  • Latest News
  • Guns
  • Politics
  • Videos
Reading: Gilead’s new twice-yearly HIV prevention injection gets FDA approval
Share
Notification Show More
Font ResizerAa
Font ResizerAa
Concealed RepublicanConcealed Republican
  • News
  • Guns
  • Politics
  • Videos
  • Home
  • Latest News
  • Guns
  • Politics
  • Videos
Have an existing account? Sign In
Follow US
  • Advertise
  • Advertise
© 2022 Foxiz News Network. Ruby Design Company. All Rights Reserved.
Concealed Republican > Blog > News > Gilead’s new twice-yearly HIV prevention injection gets FDA approval
News

Gilead’s new twice-yearly HIV prevention injection gets FDA approval

Jim Taft
Last updated: June 19, 2025 1:11 pm
By Jim Taft 2 Min Read
Share
Gilead’s new twice-yearly HIV prevention injection gets FDA approval
SHARE

NEWYou can now listen to Fox News articles!

The U.S. Food and Drug Administration (FDA) approved a new, twice-yearly shot — the first and only of its kind — to prevent HIV, the creator of the drug, Gilead Sciences, announced on Wednesday.

Sold under the name Yeztugo, the company’s injectable HIV-1 capsid inhibitor (lenacapavir) reduces the risk of sexually acquired HIV in adults and adolescents.

“This is a historic day in the decades-long fight against HIV,” said Daniel O’Day, chairman and CEO of California-based Gilead Sciences, in a press release.

ALZHEIMER’S DISEASE COULD BE PREVENTED BY ANTIVIRAL DRUG ALREADY ON MARKET

The medicine, which only needs to be administered twice a year, has shown “remarkable outcomes in clinical studies,” as Gilead claims it could transform HIV prevention.

The drug is given as an injectable under the skin that the body then slowly absorbs. Individuals must have a negative HIV-1 test prior to starting the treatment.

In large trials last year, the drug was not only nearly 100% effective in its prevention of HIV, but proved superior to once-daily oral medication like Truvada, another drug by Gilead.

A pharmacist holds a vial of lenacapavir

The journal Science named lenacapavir its 2024 “Breakthrough of the Year.”

CLICK HERE TO SIGN UP FOR OUR HEALTH NEWSLETTER

Lenacapavir uses a multi-stage approach that distinguishes it from other approved antiviral medications. 

Man at doctor's appointment

“While most antivirals act on just one stage of viral replication, lenacapavir is designed to inhibit HIV at multiple stages of its lifecycle,” states the press release from Gilead.

For more Health articles, visit www.foxnews.com/health

“Yeztugo is one of the most important scientific breakthroughs of our time and offers a very real opportunity to help end the HIV epidemic,” O’Day said in the press release.

The most commonly reported adverse reactions during clinical trials included injection site reactions, headache and nausea, according to the company.

Read the full article here

You Might Also Like

Security video shows good guy with a gun putting down shooter on busy downtown sidewalk — police say he saved many lives

Trump’s ‘big, beautiful’ agenda passes first major Senate test

Tiger Woods congratulates Rory McIlroy for Masters win

Shedeur Sanders called out by Browns GM for speeding tickets: ‘Not smart’

Everytown Attacks Concealed Carry as ‘Dangerous and Unpopular’

Share This Article
Facebook X Email Print
Previous Article Dave Portnoy Rips WNBA for Letting Marina Mabrey Shove Caitlin Clark Without Ejection [WATCH] Dave Portnoy Rips WNBA for Letting Marina Mabrey Shove Caitlin Clark Without Ejection [WATCH]
Next Article Why Congress must make Trump’s tax cuts permanent Why Congress must make Trump’s tax cuts permanent
Leave a Comment

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

- Advertisement -
Ad image

Latest News

Why Hollywood’s ‘Nobody’ is every father today
Why Hollywood’s ‘Nobody’ is every father today
News
Unearthed in Rome during subway work, ancient apartment building predates Christ
Unearthed in Rome during subway work, ancient apartment building predates Christ
News
James Comey outs himself as a Swiftie in a ‘creepy’ rant
James Comey outs himself as a Swiftie in a ‘creepy’ rant
News
California loses PREP funding after refusing to remove gender content
California loses PREP funding after refusing to remove gender content
News
Caitlin Clark returns to Fever shootaround while nursing groin injury
Caitlin Clark returns to Fever shootaround while nursing groin injury
News
Trump blasts Senate blue slip tradition blocking his judge nominees
Trump blasts Senate blue slip tradition blocking his judge nominees
News
© 2025 Concealed Republican. All Rights Reserved.
  • Privacy Policy
  • Terms of use
  • Press Release
  • Advertise
  • Contact
Welcome Back!

Sign in to your account

Username or Email Address
Password

Lost your password?